AR124178A1 - Formulación compuesta para administración oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico y un proceso para su preparación - Google Patents

Formulación compuesta para administración oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico y un proceso para su preparación

Info

Publication number
AR124178A1
AR124178A1 ARP210103303A ARP210103303A AR124178A1 AR 124178 A1 AR124178 A1 AR 124178A1 AR P210103303 A ARP210103303 A AR P210103303A AR P210103303 A ARP210103303 A AR P210103303A AR 124178 A1 AR124178 A1 AR 124178A1
Authority
AR
Argentina
Prior art keywords
indol
pyrazole
cyano
isopropyl
carboxylic acid
Prior art date
Application number
ARP210103303A
Other languages
English (en)
Inventor
Seok Cheol Yoo
Sun Lee
Duck Il Yun
Junghong Park
Hyun Ji Sun
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of AR124178A1 publication Critical patent/AR124178A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Reivindicación 1: Una formulación oral estable que comprende un principio farmacéutico activo (API), que es ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico o una sal farmacéuticamente aceptable de este y uno o más excipientes, caracterizada porque la formulación no incluye un estabilizador separado como un excipiente, y donde el 90% en peso o más del API se mantiene a 40ºC y 75% de humedad relativa durante 6 meses, o se mantiene a 80ºC y 75% de humedad relativa durante 12 días o se mantiene a 25ºC y 60% de humedad relativa durante 1 año.
ARP210103303A 2020-12-01 2021-11-30 Formulación compuesta para administración oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico y un proceso para su preparación AR124178A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20200166051 2020-12-01

Publications (1)

Publication Number Publication Date
AR124178A1 true AR124178A1 (es) 2023-02-22

Family

ID=81854222

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210103303A AR124178A1 (es) 2020-12-01 2021-11-30 Formulación compuesta para administración oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico y un proceso para su preparación

Country Status (14)

Country Link
US (1) US20240000751A1 (es)
EP (1) EP4257123A4 (es)
JP (1) JP2023551712A (es)
KR (1) KR20220077091A (es)
CN (1) CN116528852A (es)
AR (1) AR124178A1 (es)
AU (1) AU2021390901A1 (es)
CA (1) CA3197405A1 (es)
CL (1) CL2023001215A1 (es)
CO (1) CO2023008265A2 (es)
MX (1) MX2023005459A (es)
PE (1) PE20240222A1 (es)
TW (2) TW202408496A (es)
WO (1) WO2022119269A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022032A2 (en) * 2002-07-31 2004-03-18 Pharmacia Corporation Pharmaceutical dosage form comprising a sulfite compound
US20060188569A1 (en) * 2005-01-21 2006-08-24 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical formulations of zonisamide and methods for their manufacture
DK2133332T3 (da) * 2007-04-11 2013-09-30 Kissei Pharmaceutical (aza)indolderivat og anvendelse deraf til medicinske formål
TWI423962B (zh) * 2009-10-07 2014-01-21 Lg Life Sciences Ltd 有效作為黃嘌呤氧化酶抑制劑之新穎化合物、其製備方法及含該化合物之醫藥組成物
TWI548630B (zh) 2011-04-06 2016-09-11 Ｌｇ生命科學有限公司 １－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸結晶型及其製造方法
EP4218755A4 (en) * 2020-11-04 2024-03-27 Lg Chem, Ltd. METHOD FOR PRODUCING CRYSTALLINE PARTICLES OF 1-(3-CYANO-1-ISOPROPYL-INDOLE-5-YL)PYRAZOLE-4-CARBONIC ACID AND PHARMACEUTICAL COMPOSITION THEREFROM

Also Published As

Publication number Publication date
TW202408496A (zh) 2024-03-01
MX2023005459A (es) 2023-05-23
AU2021390901A9 (en) 2024-05-23
CA3197405A1 (en) 2022-06-09
WO2022119269A1 (ko) 2022-06-09
PE20240222A1 (es) 2024-02-16
KR20220077091A (ko) 2022-06-08
CL2023001215A1 (es) 2023-12-15
EP4257123A4 (en) 2024-05-08
TW202228679A (zh) 2022-08-01
JP2023551712A (ja) 2023-12-12
EP4257123A1 (en) 2023-10-11
TWI840721B (zh) 2024-05-01
CN116528852A (zh) 2023-08-01
CO2023008265A2 (es) 2023-06-30
AU2021390901A1 (en) 2023-06-08
US20240000751A1 (en) 2024-01-04

Similar Documents

Publication Publication Date Title
DOP2022000183A (es) Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead
BR112012030177A2 (pt) composto, uso do mesmo, e, composição farmacêutica
MX2016001971A (es) Composiciones farmaceuticas parenterales acuosas estables de peptidos insulinotropicos.
EA201490801A1 (ru) Композиции этанерцепта, стабилизированные комбинациями сахаров и полиолов
AR114323A1 (es) Péptidos de la cadena b de la relaxina modificados y su uso terapéutico
CL2020000625A1 (es) Proceso para formulación farmacéutica liofilizada de una proteína terapéutica.
AR114324A1 (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
BR112022009209A2 (pt) Derivado de amida e método de preparação e uso do mesmo na medicina
AR114325A1 (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
AR125250A1 (es) Composiciones de psilocibina, procedimientos de fabricación y procedimientos de uso de las mismas
UY30935A1 (es) Combinacion:-antagonista del receptor de quimioquina 1 (ccr1) -agonista del receptor de glucocorticoides- opcionalmente agonista b(beta)2, -composicion farmacéutica conteniéndola -aplicaciones.
AR124178A1 (es) Formulación compuesta para administración oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico y un proceso para su preparación
CO2017009400A2 (es) Formulación estable para administración parenteral de tapentadol
BR112023019795A2 (pt) Composições nasais compreendendo alcaftadina
CO2023005726A2 (es) Formulación sólida
ECSP22092205A (es) Composición farmacéutica acuosa de levilimab y su uso
DOP2022000004A (es) Composiciones farmacéuticas resistentes a la descarga de dosis que comprenden venirunad
BR112018072177A2 (pt) composição farmacêutica, recipiente, e, métodos para tratar e prevenir congestão nasal, infecções virais do trato respiratório e/ou inflamação da garganta
ECSP19019253A (es) Formulación estable para la administración parenteral de tapentadol
CL2022002932A1 (es) Composiciones y métodos para suministrar agentes farmacéuticamente activos
AR125366A1 (es) Formulación compuesta para administración oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico
BR112022022948A2 (pt) Comprimido mucoadesivo para o tratamento de infecções fúngicas orofaríngeas
CL2023003276A1 (es) Composición farmacéutica que contiene triterpenoides pentacíclicos
AR117298A1 (es) Aglutinante de péptido
CO2022014452A2 (es) Formulaciones líquidas de análogos de glucagón